You are here:  Home
  |  Login
  HSG Mission

The Huntington Study Group (HSG) is dedicated to the mission of seeking treatments that make a difference to those affected by Huntington disease.

  News & Events

March 2015

Dr. Samuel Frank, HSG investigator at Boston Medical College and PI of the First-HD study will be presenting data from the First-HD study at the 67th American Academy of Neurology Annual Meeting on April 22nd. Please see more information about the meeting and register on the AAN 2015 Annual Meeting website.

February 2015

The Tenth Edition of HD Insights has been released. Be sure to check it out!

January 2015

The HSG is pleased to announce dates for HSG 2015, to be held October 22-24 in Tampa, Florida, as well as the appointment of a new Director of Finance & Operations, Stevan Ramirez. See more here!

December 2014

“Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease.”  See relevant Press Release on their website.

HDSA has announced their 2015 Donald A. King Summer Research Felllowship is now accepting applications. Please see their site for more information and to apply.

November 2014

The Ninth Edition of HD Insights premiered at HSG 2014. Be sure to check it out!

The ongoing HSG trial, Pride-HD, will be featured on the next Help4HD Radio Blog show on Tuesday, November 18, as well as during the next HDSA Research Webinar Series on December 2 at noon, ET. Please be sure to tune in for both exciting and informative sessions!

October 2014

The HSG trial CREST-E announced an early study closure. Please find pertinent information regarding this decision here.

  Dedication to Huntington Disease Research

The HSG fulfills its mission greatly through clinical research for HD.

The HSG is comprised of clinical researchers worldwide who are dedicated to this mission.

If you are a research site wishing to conduct HSG trials, learn more about becoming an HSG Site.

If you wish to be contacted by the HSG about ongoing and upcoming research opportunities, please sign up for our Future Contact database.

Thank you for coming to visit our site and please continue to check back for frequent updates.

  Current HD Research Studies and Clinical Trials - Call 800-487-7671 to learn more

On-going HSG Research Studies & Clinical Trials

LEGATO-HD: a multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquinimod (0.5, 1.0, and 1.5 mg/day) as treatment in patients with Huntington's Disease. The study is sponsored by Teva Branded Pharmaceutical Products in collaboration with the HSG and EHDN.

PRIDE-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN), with sponsorship by Teva Branded Pharmaceutical Products.

SD-809 (Auspex Pharmaceuticals)

“Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease.”
See relevant Press Release on their website.

SD-809 is an investigational study drug developed by Auspex Pharmaceuticals for the treatment of chorea. First-HD and ARC-HD are Phase III clinical trials that are  evaluating SD-809’s safety, tolerability and effectiveness in reducing chorea.

First-HD is designed for subjects who have not taken tetrabenazine in the past 6 months (no longer enrolling study participants).

ARC-HD is for subjects who are currently taking tetrabenazine or those who participated in First-HD (currently enrolling study participants).

All participants are eligible for reimbursement of travel and lodging costs.  Participants in ARC-HD may be eligible to receive at no cost the study drug and medical supervision for at least 12 months.


PREDICT-HD 2.0 - Observational research study for at-risk gene positive, pre-symptomatic, and gene negative tested individuals, with headquarters at the University of Iowa, under the leadership of Dr. Jane Paulsen.

Recently Completed HSG Research Studies & Clinical Trials

(In Publication)


CREST-E: A global, multi-center, clinical trial run in collaboration with Massachusetts General Hospital investigating the effects of creatine monohydrate on the progression of Huntington disease, led by Dr. Steven Hersch.

2CARE: A multi-center, randomized, double-blind, placebo-controlled trial led by Merit Cudkowicz, Michael McDermott, and Karl Kieburtz, assesing the effects of coenzyme Q10 on inviduals with mild-to-moderate Huntington disease.

Reach2HD - A clinical research trial investigating the effects of PBT2 on invidividuals with early to mid-stage Huntington disease, led by Ray Dorsey of Johns Hopkins University and Diana Rosas of Massachusetts General Hospital.

PREQUEL: A clinical trial investigating the safety and tolerability of coenzyme Q10 for individuals with pre-manifest Huntington disease, led by Dr. Christopher Ross (John Hopkins University) and co-led by Dr. Kevin Biglan (University of Rochester).

  Donate to the HSG

The Huntington Study Group (HSG) welcomes financial contributions at any level in support of our research activities. Please click here for more information on how to contribute to the HSG and we THANK YOU for your generosity.